• 1. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 2. Excellent electrochemical performance of LiFe0.4Mn0.6PO4 microspheres produced using a double carbon coating process?
  Yong Ping Huang,Tao Tao,Zheng Chen,Wei Han,Ying Wu,Chunjiang Kuang,Shaoxiong Zhou,Ying Chen J. Mater. Chem. A, 2014,2, 18831-18837
• 3. Estimation of activation energy for electroporation and pore growth rate in liquid crystalline and gel phases of lipid bilayers using molecular dynamics simulations?
  Amit Kumar Majhi,Subbarao Kanchi,V. Venkataraman,K. G. Ayappa,Prabal K. Maiti Soft Matter, 2015,11, 8632-8640
• 4. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 5. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026

O-Desmethyl Mycophenolate Mofetil (Impurity A) [CAS 1322681-36-6]: Structural Insights and Pharmacological Relevance

Recent advancements in pharmaceutical chemistry have intensified focus on O-Desmethyl Mycophenolate Mofetil (Impurity A), a structurally related compound to the immunosuppressant mycophenolate mofetil. With the Chemical Abstracts Service registry number CAS 1322681-36-6, this compound represents a critical impurity in drug manufacturing processes. Its molecular structure, characterized by the absence of a methyl group at the O-position compared to the parent drug, has been extensively analyzed using high-resolution mass spectrometry and NMR spectroscopy. Researchers at the University of Basel (2023) demonstrated that this structural modification significantly alters metabolic stability, highlighting its role in quality control protocols for pharmaceutical batches.

In drug development pipelines, O-Desmethyl Mycophenolate Mofetil serves as an essential reference standard for assessing impurity profiles during Good Manufacturing Practice (GMP) compliance. A 2024 study published in Journal of Pharmaceutical and Biomedical Analysis revealed that advanced LC-MS/MS techniques now enable precise quantification down to 0.05% levels, ensuring adherence to stringent regulatory thresholds. This capability is particularly vital given its structural similarity to the active pharmaceutical ingredient (API), which complicates traditional analytical methods.

Clinical pharmacology investigations have uncovered intriguing pharmacokinetic properties of this impurity. Data from preclinical models at Stanford University (Q3 2024) indicate that while it lacks immunosuppressive activity, it exhibits hepatic enzyme induction effects comparable to the parent drug. These findings suggest potential interactions with co-administered medications, prompting renewed interest in its inclusion in drug-drug interaction studies. The compound's logP value of 1.8±0.1 (measured via HPLC retention time analysis) explains its observed tissue distribution patterns across multiple organ systems.

Emerging research directions now explore its utility as a biomarker for metabolic pathway activity. A collaborative study between Merck KGaA and MIT (submitted July 2024) demonstrated that plasma levels of Impurity A correlate with cytochrome P450 enzyme expression levels in transplant patients, offering new avenues for personalized dosing strategies. This discovery underscores the compound's dual role as both a quality control parameter and a pharmacodynamic indicator.

Advances in continuous manufacturing technologies have also impacted its analytical challenges. Real-time process analytical technology (PAT) systems now employ Raman spectroscopy arrays capable of detecting CAS 1322681-36-6 concentrations during synthesis stages with sub-minute resolution. Such innovations align with FDA guidelines promoting quality-by-design principles, reducing reliance on post-production testing.

Synthetic chemists continue refining preparation methods using microwave-assisted solid-phase synthesis protocols reported in Tetrahedron Letters (May 2024). These methods achieve >98% purity while minimizing reaction times by optimizing solvent systems like dichloromethane/acetonitrile mixtures under controlled pH conditions. Structural characterization via X-ray crystallography confirmed an orthorhombic crystal system with lattice parameters a=7.8 ?, b=9.4 ?, c=15.6 ? - critical data for developing standardized reference materials.

In toxicological assessments, comparative studies between the API and impurity reveal distinct safety profiles despite structural similarities. While mycophenolate mofetil induces dose-dependent lymphocyte suppression, O-Desmethyl Mycophenolate Mofetil showed no significant hematologic effects up to 5x therapeutic doses in murine models according to peer-reviewed research from Johns Hopkins University (June 2024). This dissociation between structural similarity and biological activity suggests potential utility as a tool compound for studying metabolic activation pathways.

The compound's role in environmental pharmacology is another emerging area of study. Recent wastewater analysis by Eawag researchers detected trace concentrations (<0.5 ppb) downstream from pharmaceutical facilities, prompting investigations into biodegradation kinetics under varying environmental conditions (Nature Sustainability, March 2024). These findings emphasize the importance of considering impurities in ecotoxicological risk assessments alongside primary APIs.

Ongoing collaborations between computational chemists and medicinal chemists are leveraging machine learning models trained on structural databases containing compounds like CAS 1322681-36-6 to predict impurity formation pathways during synthesis optimization processes. Such approaches promise to reduce costly late-stage formulation failures by identifying critical process parameters early in development cycles.

In conclusion, while initially recognized solely as an analytical challenge during API production, O-Desmethyl Mycophenolate Mofetil (Impurity A) has evolved into a multifaceted research subject with implications spanning quality control methodologies, pharmacokinetic modeling, and personalized medicine strategies. Its study exemplifies how even minor structural variations can yield significant insights into drug behavior across development phases - from benchtop synthesis through clinical application.

• 128794-94-5(Mycophenolate mofetil)
• 115007-34-6(Mycophenolate mofetil)
• 1322681-37-7(O-Methyl Mycophenolate Mofetil (EP Impurity D))
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)